Abstract
The scientific requirements and formats for clinical study authorizations (CSA) — IND, CTX, CTC, CTN, etc. — vary considerably from country to country. In some cases they are virtually nonexistent. A comparison is made of the situation in some of the most demanding countries — Australia, Sweden, United Kingdom, and the United States — to highlight differrences and similarities. Further, the levels of the CSAs required to proceed through Phase I–III are considered as steps which eventually culminate into marketing authorization applications (MAA). Such a stepwise development strategy is bound to result in more easily prepared MAAs which may be more quickly approved
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
